Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Regeneron's purchase is still subject to court ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Regeneron Pharmaceuticals (NASDAQ:REGN) operates within the biotechnology sector and is listed on Biggest Companies on Nasdaq ...

Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

STORY: U.S. stocks ended a choppy session mixed on Friday, with the Dow up marginally, the S&P 500 flat and the Nasdaq down ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...